59 results about "Gestational hypertension" patented technology

The present invention concerns the identification and detection of maternal serum biomarkers of pre-eclampsia and associated complications, gestational hypertension and placental insufficiency using global proteomic approaches. The invention further concerns the identification of maternal serum biomarkers for detection of pre-eclampsia and associated complications, gestational hypertension and placental insufficiency during early gestation.

The invention relates to a special clinical nutrition formula for gestational hypertension and a preparation method thereof. The special clinical nutrition formula comprises the following components: 25-35 parts of protein, 8-15 parts of fat, 35-45 parts of carbohydrate, 3-8 parts of dietary fiber, 0.6-1.2 parts of macroelement, 0.01-0.03 part of trace element, 0.005-0.02 part of fat-soluble vitamin, 0.08-0.2 part of water-soluble vitamin, 0.5-5 parts of dietary essence, 0.5-5 parts of medicinal-edible component, 0.1-1 part of natural plant compound and 0.1-0.4 part of new resource food, wherein the medicinal-edible component is at least one of flos chrysanthemi, sophora japonica, lotus leaf, wolfberry, oyster, phyllanthus emblica and radix puerariae; the components are made into powder in advance; the fat is made into powdered oil by a micro-capsule embedding technology. Through the screening and proportioning of the components, the nutrition formula provided by the invention can meet the comprehensive needs of a gestational hypertension patient; and meanwhile, by adding the component with a blood pressure reducing function, the blood pressure value of gestational hypertension is lowered, the risk of gestational hypertension is reduced, and the growth needs and normal development of a fetus are guaranteed.

A composition is provided to prevent, limit the effects of, delay the onset of, or treat one or more of the causes, symptoms or complications of gestational hypertension, preeclampsia, eclampsia and / or intrauterine growth restriction. The composition comprises a therapeutically effective amount of an antibody that reacts immunologically with or binds digoxin and has a high dose of digoxin binding capacity as the active ingredient. There is also provided a method of preventing, limiting the effects of, delaying the onset of, or treating a cause, symptom or complication of gestational hypertension, preeclampsia, eclampsia or intrauterine growth restriction, comprising the step of administering to a mammal a composition comprising a therapeutically effective amount of an antibody that reacts immunologically with or binds digoxin and has a high dose of digoxin binding capacity.

The invention relates to methods and compositions for identifying subjects having, or predisposed to having, gestational diabetes, preeclampsia, and gestational hypertension. The methods are applicable to urine and / or blood samples and can be conducted prior to the third trimester of pregnancy.

The present invention relates to the prognosis and risk assessment in pregnant women to develop pregnancy-induced hypertension and / or preeclampsia by the determination of marker levels.

The invention discloses a monitor for gestational hypertension risk on the basis of physiology, biochemistry and blood dynamics information, relating to the technical field of medical equipment. The monitor is characterized by being a device which can input physiology, biochemistry and blood dynamics information of gestational women in an array mode and expresses the gestational hypertension risk by numerical values, bar codes and colors. The device comprises a gestational woman physiology and biochemistry information induction module, a gestational woman blood dynamics information induction module, a logic switch array formation module for the physiology, biochemistry and blood dynamics information of the gestational hypertension risk, a bar code generation module for the gestational hypertension risk, a logic switch value regression calculation module for the gestational hypertension risk, a color generation module for the gestational hypertension risk and a display output module for the gestational hypertension risk. The monitor can automatically induce the physiology, biochemistry and blood dynamics information of the gestational women, and effectively improves the automation degree and the informatization degree for monitoring the gestational hypertension.

The present description relates to a method for determining the risk of a pregnant woman developing a hypertensive disorder, more specifically gestational hyper-tension or late onset preeclampsia. The present description provides methods useful for determining risk that a pregnant individual will develop a hypertensive disorder or condition of pregnancy, such as gestational hypertension, early preeclampsia, late preeclampsia and related disorders. Several useful combinations of biochemical markers and related clinical population studies are described herein. Additionally, it is proposed herein that certain sets of biochemical markers can be used to determine risk of multiple hypertensive disorders in a single screen. The biochemical markers are PlGF, Activin A and optionally P-Selectin.

A traditional Chinese medicine for curing pregnancy-induced hypertension syndrome belongs to a traditional Chinese medicine for curing pregnancy diseases. The components contain: 15g of viscum album, 15g of spina date seed, 20g of eucommia bark, 20g of salvia miltiorrhiza, 10g of rhizoma gastrodiae, 10g of largehead atractylodes rhizome, 10g of rhizoma atractylodis, 10g of dried orange peel, 12g of shell of areca nut, 12g of tuckahoe, 6g of cassia twig, 6g of amomum villosum and 6g of liquorice. The substances in the prescription are made from natural traditional Chinese medicine plus traditional preparing methods. The materials are easy to collect, the prescription and the preparation methods are simple, and the cost of medicine preparation is low. The compatibility of the traditional Chinese medicine is simple; the medicine used in the prescription is fully natural herbal medicine, which is easy to collect and use; the preparation method is simple; the effects for taking and curing are good; the cost of the medicine is low, and the medicine is in particular suitable for the people living in remote villages far from towns; the cost is low for curing the people suffering from pregnancy-induced hypertension syndrome, which solves the problem that the local area lacks medical conditions to cure the disease because of low household income and poor living condition.

Provided are: a method for predicting the onset of pregnancy-induced hypertension (PIH) by precisely detecting abnormalities that occur before the onset of PIH (where such abnormalities have been impossible to detect by various conventional testing methods for PIH) while imposing less of a burden on a subject; a method for evaluating a fetus and placental functions in PIH; and a method for detecting PIH, which comprises measuring the level of human lipocalin-type prostaglandin D synthase (L-PGDS) in a body fluid sample collected from a subject.

The invention relates to the technical field of biomedical detection. Pregnancy-hypertension syndrome is one of the critical factors resulting in death for gravida, puerpera, etus and infant. The current detection method is carried out mainly relying on the symptom existing clinically as well as based on some biochemical indicators; in fact, pregnancy-hypertension syndrome exists in early pregnantstage, while early detection landmark is lack in clinical practice for early detection and prevention of the disease. The invention aims at providing a hsa-mir-210 kit for detecting pregnancy-hypertension syndrome and a detection method thereof. By detecting variation of the hsa-mir-210 content in plasma or serum, the invention can more effectively carry out early detection on patients with pregnancy-hypertension syndrome and discover high-risk people with pregnancy-hypertension syndrome so as to prevent the disease effectively in time, and decrease occurrence of pregnancy-hypertension syndrome as well as related complication.

A method for the early prediction of risk of hypertensive disorders in pregnant women, including for example eclampsia, mild pre-eclampsia, chronic hypertension, EPH gestosis, gestational hypertension, superimposed pre-eclampsia, HELLP syndrome, or nephropathy.

Gestational hypertension relates to a specific disease in the gestation period. The invention establishes an appropriate animal model for imitating the gestational hypertension sign of human, and facilitates knowing the occurrence and the development process of pathology of the gestational hypertension sign, understanding nosetiological factors relevant to the gestational hypertension sign, and establishing a clinical diagnosis index, so that the invention has great significance for screening treatment medicines, and the invention is also favorable for researching the influence of the gestational hypertension sign for growth of the filial generation in detail and provides experiment references for intervening treatment in advance. The invention provides a method for preparing an animal model used for hypertension nosogenesis and a treatment method thereof through chill stimulation, which is used for establishing the gestational hypertension mouse model with stability, convenience and reasonable cost, so as to smoothly perform the research of nosogenesis and the treatment method of the disease.

The invention relates to a Chinese patent medicament for treating intractable hypertension, which comprises the following Chinese herbal medicaments in part by weight: 50 to 100 parts of seabuckthorn, 80 to 100 parts of wild thyme, 100 to 150 parts of madagascar periwinkle herb, 100 to 150 parts of ganoderma lucidum karst, 150 to 300 parts of black fungus, 80 to 100 parts of emblic root, 50 to 100 parts of salidroside, 50 to 100 parts of devilpepper root, 200 to 300 parts of kudzuvine root, 200 to 300 parts of hawthorn root and 200 to 300 parts of cassia seed. The medicaments are subjected to reasonable compatibility and are complementary in medicinal effects, so the Chinese patent medicament has good effect of reducing blood pressure, can address both symptoms and root causes, is suitable for patients who suffer from senile hypertension, juvenile hypertension, gestational hypertension, salt-sensitive hypertension and the like and particularly has the special and obvious curative effect on patients who suffer from refractory hypertension; and the Chinese patent medicament has the cure rate of 82.7 percent on the refractory hypertension, and has the total cure rate of 68.6 percent, total effectual rate (cure and effect producing) of 89.3 percent and the total effective rate of 100 percent on various kinds of hypertension, and the hypertension does not relapse after being cured.

The invention discloses a Corin gene variant and application thereof.Specifically, compared with a Corin gene shown in SEQ ID NO:1, the Corin gene variant has any of variations including c.G1203A, c.C2753T, c.C2928T and c.G1747T, and a polypeptide encoded through the variant has any of variations including p.R349H, p.P866S, p.T924M and p.R530S.The variant and the polypeptide can be used for preparing a hypertension diagnosis reagent and a gestational hypertension diagnosis reagent, detecting and screening people on a large scale and finding whether a testee suffers from hypertension sensibilization; by detecting peripheral blood, the pathogenesis of patients suffering from hypertension and gestational hypertension can be clearly obtained, and the variant is easy and convenient to use, high in specificity and capable of providing guidance for clinical treatment.

The present invention provides a method for preventing or ameliorating neural damage in a mammalian fetus or a newborn infant, which is caused by maternal gestational hypertension (GH). The method includes orally administering germination activated sporoderm-broken Ganoderma lucidum spores (“GLSs”) to a pregnant mammal having GH. The neural damage includes a decrease in hippocampal cell proliferation and neuron number. The present invention further provides a method for preventing or ameliorating the increased expression of hippocampal hypoxia inducible factor (HIF-1a) and vascular endothelial growth factor (VEGF) in a mammalian embryo caused by maternal GH.

The invention relates to a method for curing edema of a pregnant woman during pregnancy period. At the later stage of pregnancy, hand edema and foot edema can easily occur to the pregnant woman. If the edema is not serious, edema can only appears on ankles and shanks. If the edema is serious, the edema can spread to upper legs, arms, and even the whole body of the pregnant woman. Physical and psychological health of the pregnant woman is seriously affected. If the edema can not be cured timely, diseases such as gestational hypertension can be caused to the pregnant woman at the later stage of the pregnancy, and the consequence can not be imagined. The pregnant woman can not take or use drugs in market freely due to the fact that the drug can affect the pregnant woman and even affect the development of a fetus. The method for curing the edema of the pregnant woman during pregnancy period both has functions of outshining blood, clearing heat, and eliminating the edema, and has functions of tonifying spleen and preventing miscarriage. Multiple purposes can be achieved.

The present invention relates to the use of a steroid in the manufacture of a pharmaceutical composition for use in the therapeutic or prophylactic treatment of a hypertensive disorder of pregnancy (HDP) or fetal growth retardation, said treatment comprising administering to a female mammal a steroid selected from the group consisting of: substances represented by the following formula (formula I) in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1 - 5 carbon atoms; each of R5, R6, R7 is a hydroxyl group; no more than 3 of R1, R2, R3, R4 are hydrogen atoms; precursors of such substances; and mixtures of one or more of the aforementioned substances and / or precursors.

The invention relates to a traditional Chinese medicine for treating gestational hypertension. The traditional Chinese medicine is prepared by the following medicines: rhizoma atractylodis macrocephalae, poria peel, pericarpium arecae, dried tangerine orange peel, dried rehmannia root, glehnia root, fructus lycii, radix ophiopogonis, radix paeoniae alba, szechwan chinaberry fruit, herba taxilli, concha haliotidis and radix salviae miltiorrhizae. 700ml of water is added into medicine to be decocted into 200ml of primary decoction, 500ml of water is added to be decocted into 200ml of secondary decoction, and patients take twice per day on an empty stomach in the morning and at night.

A lentiviral vector was used to produce non-human animals that express human sFLT1 specifically in the murine placenta, to provide model animals of diseases such as pregnancy-induced hypertension syndrome that are close to the clinical conditions, methods for producing the model animals, methods of screening for candidate compounds as therapeutic agents for diseases such as pregnancy-induced hypertension syndrome by using the model animals, and therapeutic agents for diseases such as pregnancy-induced hypertension syndrome. As a result, the model animals were found to exhibit symptoms that are very close to the clinical conditions in human, which are presentation of hypertension as well as placental insufficiency, intrauterine growth retardation, glomerulosclerosis, and proteinuria during pregnancy, and improvement of those symptoms postpartum. Furthermore, when pravastatin was administered to this model animal, it was found that diseases such as pregnancy-induced hypertension syndrome were improved by the activation of placenta-derived growth factor (PIGF) which antagonizes sFLT1.

The invention provides a reagent of a marker composition capable of detecting gestational hypertension associated diseases. The marker composition is prepared from glutamate-rich SH3 domain binding protein 3, plasma protease inhibitory protein C1, relaxin, serine protease inhibitory protein A5, clusterin, serine protease inhibitory protein A4, serine protease peptidase inhibitory protein C1, phosphatidylinositol-glycan biosynthesis type F protein, pregnancy-associated plasma protein, insulin-like growth factors, calnexin and attractin. The accuracy rate of the marker composition provided by the invention for detecting gestational hypertension is 98% which meets the requirement for clinical disease screening and can not be realized by the existing gestational hypertension detection technology.

The invention discloses a natural lead-discharging condiment and a processing method thereof, and relates to the technical field of processing of condiments. According to the natural lead-dischargingcondiment disclosed by the invention, various edible mushrooms are used as main materials, auxiliary materials of kirilow groundsel herbs, olive leaves and the like are used for cooperation, and the natural lead-discharging condiment is prepared; and the natural lead-discharging condiment does not have any chemical reagents, so that the eating safety of pregnant women can be guaranteed. The prepared natural lead-discharging condiment not only can complement nutrient components needed by human bodies, but also can accelerate lead removal in blood of the pregnant women, so that damage to bodiesand foetuses caused by the situation that the lead content of the bodies exceeds the standard can be avoided; and besides, after the prepared condiment disclosed by the invention is eaten for a long term, gestational hypertension can be relieved.

The invention discloses a medicine for treating qi depression phlegm accumulation type gestational hypertension and a preparation method thereof. The raw medicinal materials in the medicine include Japanese balanophora, dried tangerine peel, delphinium brunnonianum royle, costusroot, rongkol, finger citron, holy basil, citron, textile screw pine shoot, armeniaca mume, margarya melanoide, margarya melanoide, sarmentose pepper herb, semen raphani, ligularia lessicotal, paederia scandens, prickly poppy, semen cassiae, Japanese inula herb, rhizome of spiny lasia spinyelephantsear, ganoderma lucidum, valerian, ligusticum, arabic cowry shell, nux prinsepiae, lemmaphyllum microphyllum, uncaria, adenophora tetraphylla, flowers of l.chinense var.rubrum, fructus broussonetiae and blumea balsamifera. The medicine for treating qi depression phlegm accumulation type gestational hypertension has the effects of strengthening the spleen, regulating qi-flowing for eliminating phlegm, and mainly treating qi depression phlegm accumulation type gestational hypertension, and has the advantages of taking effect soon, and being high in efficiency, definite in curative effect, short in treatment course, free of side effects and the like on the aspect of treating qi depression phlegm accumulation type gestational hypertension.

The invention belongs to the field of medicines and particularly relates to a medicine composition for treating gestational hypertension complicated with preeclampsia. The medicine composition is prepared from fructus lycii, flos chrysanthemi, radix rehmanniae preparata, common macrocarpium fruit, cortex moutan, rhizoma dioscoreae, poria cocos, rhizoma alismatis and omphalia by extracting throughwater decoction and alcohol deposition methods; a preferable preparation of the medicine composition is an oral liquid preparation. The composition is capable of obviously reducing blood pressure andurine protein of rats suffering from the gestational hypertension complicated with the preeclampsia, so that the composition is capable of relieving gestational hypertension symptom and preventing occurrence of eclampsia.

The invention discloses a method for hypertensive disorders of pregnancy by combining D-dimer with alpha fetoprotein and free[beta]-hCG in maternal serum during mid-pregnancy. The method comprises thesteps of dividing pregnant women into three case groups and a control group according to the existence or absence of gestational hypertension GH, preeclampsia PE and severe preeclampsia group SPE; detecting the levels of D-dimers, AFP (alpha fetoprotein) and free[beta]-HCG of the four groups of pregnant woman serum specimens, and representing the measured levels of the D-dimers, the AFP and the free[beta]-HCG by the median multiples MoM of the weight and the gestational weeks; and comparing median multiple MoM distribution conditions, and constructing a risk calculation model by using MOM values in combination with the weight and the gestational weeks. The method has the beneficial effects that the risk calculation model constructed by calibrating MOM values of the D-dimer, the AFP and the free[beta]-HCG in serum of the pregnant woman in combination with the weight and the gestational weeks has relatively high sensitivity and specificity when being used for screening the hypertensivedisorders of pregnancy HDP, and can become a new marker for predicting the hypertensive disorders of pregnancy HDP.

The invention relates to the compounds of formula I, formula II and / or formula III or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compound of formula I, formula II or formula III, and methods for treating or preventing Parkinson's disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, subcutaneous, depot, intramuscular, syrup, or injection. Such compositions may be used to treatment or management of Parkinson's disease as well as scleroderma, restless leg syndrome, hypertension and gestational hypertension.

The invention provides a reagent capable of detecting a hypertensive disorders in pregnancy associated marker composition. The marker composition comprises three or more of calnexin, attractin, clusterin, cytokeratin 18, pregnancy-specific beta-1-glycoprotein 4, SH3 domain-binding glutamic acid-rich-like protein 3, serine protease inhibitor A4, plasma serine protease inhibitor A5, serpin peptidaseinhibitor, clade C member 1, relaxin-3, APOC4, Annexin A1, and insulin-like growth factor-binding protein 2. The marker composition provided by the invention has gestational hypertension detection accuracy up to 90% or more meets the requirements of clinical disease screening, which are unachievable by the current gestational hypertension detection technology.